160R8Zbh0X
INCB13739 is developed as a new treatment for type 2 diabetes.  It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.